Pioneering the Future of Infection Control
Advanced HOCl-Based Solutions That Remain Effective Where Traditional Antimicrobials Fail
Revolutionizing Infection Care
Pioneering the Future of Infection Control
Spectrum Antimicrobials develops next-generation medical devices and drug candidates engineered to overcome the critical limitations of conventional infection control, remaining stable and effective in the presence of blood serum, biofilms, and challenging clinical environments.
2018 - Initial Research
Spectrum Antimicrobials founded by Hoji Alimi to address the urgent global need for effective antimicrobial solutions. Initial research focused on developing proprietary HOCl-based chemistries with enhanced stability and efficacy.
2019 - GMP Manufacturing Facility
Established FDA-registered 14,000 sq. ft. cGMP manufacturing headquarters in Petaluma, California, with advanced bottling capabilities producing 20,000+ units per hour.
2020-2021 - Regulatory Approvals
Achieved FDA 510(k) clearance for Spectricept® Skin & Wound Cleanser and CE Mark approval for hand sanitizer formulation. Independent laboratory validation confirmed superior efficacy against C. difficile spores and biofilms.
2022 - International Partnerships
Licensed SPX-001 to SpectrumX for UK and European markets. Established partnership with Triumph Medical Services for Vetricept distribution in the United States, expanding global reach of innovative infection control solutions.
2023-2024 - Pipeline Expansion
Advanced SPX-001 development for pulmonary infections with proven efficacy in presence of serum and mucus. Expanded R&D operations in San Diego focusing on novel antimicrobial platforms targeting antibiotic-resistant pathogens.
Innovative Infection Care
Leadership Committed to Scientific Excellence
Our multidisciplinary team combines deep expertise in microbiology, chemistry, regulatory affairs, and clinical medicine.
Executive Team

Hoji Alimi
Founder, Chairman, CEO Head of product Development

Bill Watson
Co-founder, Executive VP of Strategic Business Alliances

Ernie Bravoe
Contracted Derm/Plastics -Consultant

James Lodigiani
Contracted US Sales –Consultant

Jerry Stonemetz MD
Chief Medical Officer

Sameer Harish
Director of Finance

James Stanley
Director of Business Dev
Management Team

Stephanie Alimi
Senior Director of Operations and Manufacturing

Antoinette Douglas
Senior Director of Regulatory Affairs and Quality Assurance

Jerry Stonemetz MD
Medical Affairs Director

Sameer Harish
Director of Finance

Diana Watson
Director of Business Dev

James Stanley
Director of Business Dev

Greg Madick
Controller
Engineering and Operations Team

Will Smith
Manufacturing Engineer

Larry Rogers
Manufacturing engineer

Brean Aquino
Manufacturing Engineer
Quality Assurance and Control

Gayathri Lekha Nair
Quality Engineering

Nicholas Alimi
Quality Control and R&D Microbiologist

Pablo Fernandez
Quality Assurance Manager
Research and Development

Mohammad Esmaeili
Co-founder and VP of Engineering and Chemistry R&D

Hoji Alimi
Head of Product Innovation

Nicholas Alimi
Microbiologist

Demsin Bet Adam
Protein Chemistry
Principles Driving Our Mission
At Spectrum Antimicrobials, scientific rigor guides every decision—our formulations undergo rigorous independent testing to validate safety, efficacy, and stability in real-world clinical conditions. We develop patient-centered solutions that address unmet clinical needs while reducing infection risk for patients and healthcare workers. Committed to responsible stewardship, our chemistries eradicate pathogens without promoting antimicrobial resistance, preserving antibiotic effectiveness for future generations. Through transparent collaboration with clinical researchers, regulatory bodies, and industry partners, we advance infection control science that makes a measurable difference in global healthcare.
- Scientific Rigor
- Patient-Centered Innovation
- Responsible Stewardship
- Partnership & Transparency
Infection Care Leadership
Advancing Infection Control Through Chemistry
- Proprietary HOCl platforms effective against antibiotic-resistant bacteria, viruses, fungi, and spores
- Proven stability in 5% serum and near-freezing temperatures—overcoming traditional HOCl limitations
- FDA-cleared medical devices and advancing drug candidates for pulmonary infections